

### Company details

Name of entity:	Genetic Signatures Limited
ABN:	30 095 913 205
Reporting period:	For the half-year ended 31 December 2025
Previous period:	For the half-year ended 31 December 2024

## 2. Results for announcement to the market

				\$'000s
Revenues from ordinary activities	up	2%	to	\$8,681
Loss from ordinary activities after tax attributable to the owners of Genetic Signatures Limited	down	58%	to	(\$6,365)
Loss for the half-year attributable to the owners of Genetic Signatures Limited	down	58%	to	(\$6,365)

### Dividends

No dividend has been declared for the half-year ended 31 December 2025.

### Comments

The loss for the Group after providing for income tax amounted to \$6,365,000 (31 December 2024: \$15,200,000)

Further information on the results is detailed in the 'Review of operations' section of the Directors' report which is part of the Half-Year Report.

## 3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	19.4	24.1

## 4. Control gained over entities

Not applicable.

## 5. Loss of control over entities

Not applicable.

**6. Details of associates and joint venture entities**

Not applicable.

**7. Audit qualification or review**

*Details of review dispute or qualification (if any):*

The financial statements were subject to a review by the auditors and the review report is attached as part of the Half Year Report.

**8. Attachments**

*Details of attachments (if any):*


The Half Year Report of Genetic Signatures Limited for the half-year ended 31 December 2025 is attached.

**9. Signed**



Caroline Waldron  
Independent Chair  
Sydney

Date: 26 February 2026



## **Genetic Signatures Limited**

**ABN 30 095 913 205**

**Half Year Report - 31 December 2025**

**Genetic Signatures Limited**  
**Directors' Report**  
**31 December 2025**

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity' or 'Group') consisting of Genetic Signatures Limited (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 31 December 2025.

**Directors**

The following persons were directors of Genetic Signatures Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Caroline Waldron  
Michael Aicher  
Neil Gunn  
Jenny Harry  
Anne Lockwood

**Principal activities**

During the financial half-year, the principal activities of the consolidated entity consisted of the research and development into identifying and commercialisation of molecular diagnostics products to aid in the diagnosis of infectious diseases and the sale of associated products into the diagnostic and research marketplaces.

**Review of operations**

**Financial Results**

Genetic Signatures reported revenue of \$8.7 million for the half year (\$8.5 million 1H FY25). Revenue was driven primarily by respiratory testing demand in Australia during the winter season, together with contributions from the EMEA region and the United States.

Gross margin of \$4.8 million (GP margin, 55.7%) compared to \$5.0 million (1H FY25, GP margin 58.8%) declined for the period by \$0.2 million driven by increased consumable costs for respiratory test kits.

A focus on cost discipline, resulted in a reduction in operating expenses of \$0.6 million for the half. An increase in other income of \$1.6 million, largely from the Research and Development Tax Incentive program drove a reduction in operating losses, with the Group reporting a net loss of \$6.4 million for the half year (\$8.4 million 1H FY25 (\$15.2 million including non-recurring impairment expenses)).

As at 31 December 2025, Genetic Signatures held \$29.9 million in cash and cash equivalents including term deposits classified as other financial assets, a decline of \$1.4 million from \$31.3 million at 30 June 2025. During the half year, the Company received \$4.4 million under the Research and Development Tax Incentive program for eligible expenditures incurred in the financial year ended 30 June 2025 and used \$5.2 million in operating activities and \$0.6 million on plant and equipment.

**Supporting initial US customer sites to increase throughput**

The Company continued to work closely with its three contracted customers to implement the EasyScreen™ Gastrointestinal Parasite Detection Kit, providing hands-on commercial and technical support to ensure a smooth onboarding and integration into routine testing workflows.

During Q2 FY26, a second contracted customer went live, with products delivered to site for go-live. The third customer has progressed through implementation activities and operational readiness, with testing expected to commence during the current quarter.

The sales team remains engaged with all contracted customers to support increased testing volumes, focusing on optimising workflows, expanding use cases, and embedding EasyScreen™ into standard diagnostic protocols. These initial deployments are now functioning as reference sites, demonstrating clinical and operational value and supporting further customer engagement and conversion across the pipeline.

### **Team engaged in EMEA to support evaluations of GI portfolio**

The team continued to work with multiple NHS trusts in the UK, where Genetic Signatures' GI viral, bacterial, and parasite test kits are being used in hospital settings to support infection control and outbreak prevention. To date, these engagements have generated supportive clinical data, reinforcing the value of our proposition to a growing number of potential clients. The team continued to pursue further evaluations to facilitate future growth in this region. Genetic Signatures continues to work with external distribution partners across the EMEA region.

### **Progress on new instruments and software and R&D**

Development progressed on the Company's new instrument and software platform, in collaboration with Tecan Group and Repado. Phase II will focus on integrated hardware and software customisation, enabling workflow optimisation, laboratory analytics and enhanced service capability.

A comprehensive market assessment, incorporating feedback from more than 200 industry professionals, is shaping the expanded 3base® syndromic testing menu to be launched alongside the new platform.

### **Leadership change at Genetic Signatures**

On the 2<sup>nd</sup> of February 2026 the Company announced the appointment of Maria Halasz as CEO effective the 2<sup>nd</sup> of March 2026, following the departure of Allison Rossiter. Ms Halasz has substantial experience leading commercialising in the life science sector including diagnostics, having served for 14 years as Chief Executive Officer and Managing Director of Anagenics Limited (formerly Cellmid Limited, ASX: AN1).

On the 6<sup>th</sup> February 2026 the Company announced the appointment of Non-Executive Director Anne Lockwood as interim Managing Director. Mrs Lockwood will assume the role of Managing Director for a six-month period, after which the Board will review the Company's longer-term management arrangements. Given Anne's in-depth experience as a CFO, the appointment of a permanent CFO will be deferred during this period.

During the half year, Dr Susanne Pedersen was appointed Chief Technology Officer. Dr Pedersen holds a PhD in molecular biology and has more than 25 years' experience in the development and commercialisation of molecular in vitro diagnostic products.

### **Outlook**

Looking ahead, the Company remains focused on strengthening its presence in Australia while accelerating global expansion. The Board remains confident in the company's strategy to continue diversifying revenue by growing international markets beyond its current primarily domestic business.

The Board has commenced a detailed review of the operational and financial performance of the business, including a line-by-line analyses of its operating costs. This review is aiming to appropriately reduce the operating costs proportionately to the business with savings being realised over FY27.

In addition the Board has commenced a review of how best to deliver shareholder value. The Company has appointed advisors to support this process. The Board emphasises that no decisions have been made but all aspects of the Company will be reviewed. The Company will keep shareholders informed in accordance with its continuous disclosure obligations.

The Board would like to thank shareholders for their on-going patience as we move through the transition of leadership and assess our strategic options.

### **Significant changes in the state of affairs**

Other than the leadership changes outlined above. No significant change in the state of affairs of the Group has occurred since the close of the period.

**Genetic Signatures Limited**  
**Directors' report**  
**31 December 2025**

**Auditor's independence declaration**


A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out on page 4.

**Rounding of Amounts**

The company is of a kind referred to in ASIC Legislative Instrument 2016/191, relating to the 'rounding off' of amounts. Amounts in this report have been rounded off in accordance with the instrument to the nearest thousand dollars, or in certain cases, to the nearest dollar.

This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the directors



Caroline Waldron  
Director

26 February 2026  
Sydney



Tel: +61 2 9251 4100  
Fax: +61 2 9240 9821  
www.bdo.com.au

Parkline Place  
Level 25, 252 Pitt Street  
Sydney NSW 2000  
Australia

**DECLARATION OF INDEPENDENCE BY RAJNIL KUMAR TO THE DIRECTORS OF COMPANY GENETIC SIGNATURES LIMITED**

As lead auditor for the review of Genetic Signatures Limited for the half-year ended 31 December 2025, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
2. No contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Genetic Signatures Limited and the entities it controlled during the period.

A handwritten signature in black ink, appearing to read 'Rajnil Kumar', written in a cursive style.

Rajnil Kumar  
Director

**BDO Audit Pty Ltd**

Sydney, 26 February 2026

## Genetic Signatures Limited

### Contents

31 December 2025

#### Contents

Consolidated statement of profit or loss and other comprehensive income	5
Consolidated statement of financial position	6
Consolidated statement of changes in equity	7
Consolidated statement of cash flows	8
Notes to the consolidated financial statements	9
Directors' declaration	16
Independent auditor's review report to the members of Genetic Signatures Limited	17

Genetic Signatures Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business are:

#### Registered office

7 Eliza Street  
Newtown NSW 2042

#### Principal place of business

7 Eliza Street  
Newtown NSW 2042

A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 26 February 2026.

**Genetic Signatures Limited**  
**Consolidated statement of profit or loss and other comprehensive income**  
**For the half-year ended 31 December 2025**

		<b>Consolidated</b>	
	<b>Note</b>	<b>31 Dec 2025</b>	<b>31 Dec 2024</b>
		<b>\$'000s</b>	<b>\$'000s</b>
Revenue	4	8,681	8,499
Other income	4	2,507	873
<b>Expenses</b>			
Cost of materials used		(3,847)	(3,497)
Freight on materials & finished goods		(520)	(487)
Employee benefits expense		(8,124)	(8,689)
Directors' and Consultancy fees		(674)	(469)
Depreciation and amortisation expense		(1,067)	(1,240)
Impairment expenses	5	-	(6,801)
Scientific consumables & clinical trials		(1,345)	(1,129)
Software expenses		(388)	(343)
Travel and marketing		(644)	(532)
Other expenses		(916)	(1,340)
Finance costs		(28)	(45)
<b>(Loss) before income tax expense</b>		<b>(6,365)</b>	<b>(15,200)</b>
Income tax expense		-	-
<b>(Loss) after income tax expense for the half-year</b>		<b>(6,365)</b>	<b>(15,200)</b>
<b>Other comprehensive income</b>			
<b>Items that may be reclassified subsequently to profit or loss</b>			
Foreign currency difference on translation of foreign operations		(181)	205
<b>Other comprehensive loss for the half-year</b>		<b>(181)</b>	<b>205</b>
<b>Total comprehensive income for the half-year</b>		<b>(6,546)</b>	<b>(14,995)</b>
<b>(Loss) for the half-year is attributable to:</b>			
Owners of Genetic Signatures Limited		(6,365)	(15,200)
		<u>(6,365)</u>	<u>(15,200)</u>
<b>Total comprehensive income for the half-year is attributable to:</b>			
Owners of Genetic Signatures Limited		(6,546)	(14,995)
		<u>(6,546)</u>	<u>(14,995)</u>
		<b>Cents</b>	<b>Cents</b>
Basic loss per share	13	(2.80)	(6.88)
Diluted loss per share	13	(2.80)	(6.88)

*The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes*

**Genetic Signatures Limited**  
**Consolidated statement of financial position**  
**As at 31 December 2025**

		<b>Consolidated</b>	
	<b>Note</b>	<b>31 Dec 2025</b>	<b>30 Jun 2025</b>
		<b>\$'000s</b>	<b>\$'000s</b>
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents		17,190	7,473
Trade and other receivables	6	2,707	3,379
Financial assets at amortised cost	7	12,680	23,822
Inventories		8,540	9,064
Government grant receivable		1,842	4,238
<b>Total current assets</b>		<u>42,959</u>	<u>47,976</u>
<b>Non-Current Assets</b>			
Property, plant and equipment		5,572	5,915
Right of use assets		508	740
<b>Total non-current assets</b>		<u>6,080</u>	<u>6,655</u>
<b>Total assets</b>		49,039	54,631
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables		3,629	2,931
Lease liabilities		465	439
Employee benefits		687	731
<b>Total current liabilities</b>		<u>4,781</u>	<u>4,101</u>
<b>Non-current liabilities</b>			
Lease liabilities		94	352
Employee benefits		73	85
<b>Total non-current liabilities</b>		<u>167</u>	<u>437</u>
<b>Total liabilities</b>		<u>4,948</u>	<u>4,538</u>
<b>Net assets</b>		<u>44,091</u>	<u>50,093</u>
<b>Equity</b>			
Issued capital		127,645	127,645
Reserves		9,924	9,561
Accumulated losses		(93,478)	(87,113)
<b>Total equity</b>		<u>44,091</u>	<u>50,093</u>

*The above consolidated statement of financial position should be read in conjunction with the accompanying notes*

**Genetic Signatures Limited**  
**Consolidated statement of changes in equity**  
**For the half-year ended 31 December 2025**

<b>Consolidated</b>	<b>Issued capital \$'000s</b>	<b>Share based payment reserves \$'000s</b>	<b>Foreign currency translation reserves \$'000s</b>	<b>Accumulated losses \$'000s</b>	<b>Total Equity \$'000s</b>
Balance at 1 July 2024	119,430	8,259	423	(67,009)	61,103
Loss after income tax expense for the half-year	-	-	-	(15,200)	(15,200)
Other comprehensive income	-	-	205	-	205
<b>Total comprehensive profit for the half-year</b>	<b>-</b>	<b>-</b>	<b>205</b>	<b>(15,200)</b>	<b>(14,995)</b>
Share issues on conversion of options, net of transaction costs	8,215	-	-	-	8,215
Forfeiture of share-based payments	-	(421)	-	-	(421)
Share-based payments expense	-	687	-	-	687
<b>Balance at 31 December 2024</b>	<b>127,645</b>	<b>8,525</b>	<b>628</b>	<b>(82,209)</b>	<b>54,589</b>

<b>Consolidated</b>	<b>Issued capital \$'000s</b>	<b>Share based payment reserves \$'000s</b>	<b>Foreign currency translation reserves \$'000s</b>	<b>Accumulated losses \$'000s</b>	<b>Total Equity \$'000s</b>
Balance at 1 July 2025	127,645	8,999	562	(87,113)	50,093
Loss after income tax expense for the half-year	-	-	-	(6,365)	(6,365)
Other comprehensive income	-	-	(181)	-	(181)
<b>Total comprehensive profit for the half-year</b>	<b>-</b>	<b>-</b>	<b>(181)</b>	<b>(6,365)</b>	<b>(6,546)</b>
Forfeiture of share-based payments	-	(97)	-	-	(97)
Share-based payments expense	-	641	-	-	641
<b>Balance at 31 December 2025</b>	<b>127,645</b>	<b>9,543</b>	<b>381</b>	<b>(93,478)</b>	<b>44,091</b>

*The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes*

**Genetic Signatures Limited**  
**Consolidated statement of cash flows**  
**For the half-year ended 31 December 2025**

	<b>Consolidated</b>	
	<b>31 Dec 2025</b>	<b>31 Dec 2024</b>
	<b>\$'000</b>	<b>\$'000</b>
<b>Cash flows from operating activities</b>		
Receipts from customers (inclusive of GST)	10,147	10,308
Payments to suppliers and employees (inclusive of GST)	(15,564)	(18,755)
Interest received	714	450
Interest paid	(28)	(45)
Government grant received	4,382	5,002
	<u>          </u>	<u>          </u>
Net cash used in operating activities	(349)	(3,040)
<b>Cash flows from investing activities</b>		
Proceeds from redemption of financial assets	10,900	-
Payments for property, plant and equipment	(599)	(181)
Payments for intangibles	-	(249)
	<u>          </u>	<u>          </u>
Net cash used in/provided by investing activities	10,301	(430)
<b>Cash flows from financing activities</b>		
Proceeds from issue of shares	-	8,769
Share issue costs	-	(554)
Principal elements of lease payments	(233)	(208)
	<u>          </u>	<u>          </u>
Net cash used in/provided by financing activities	(233)	8,007
<b>Net increase in cash and cash equivalents</b>	9,719	4,537
Cash and cash equivalents at the beginning of the financial half-year	7,473	36,252
Effects of exchange rate changes on cash and cash equivalents	(2)	4
	<u>          </u>	<u>          </u>
<b>Cash and cash equivalents at the end of the financial half-year</b>	<u><u>17,190</u></u>	<u><u>40,793</u></u>

*The above consolidated statement of cash flows should be read in conjunction with the accompanying notes*

**Genetic Signatures Limited**  
**Notes to the consolidated financial statements**  
**For the half-year ended 31 December 2025**

**Note 1. Significant accounting policies**

**Basis of preparation of half-year report**

These general-purpose financial statements for the half-year reporting period ended 31 December 2025 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

The half-year report does not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2025 and any public announcements made by the company during the half year reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The accounting policies adopted in the preparation of the interim consolidated financial statements are consistent with those followed in the preparation of the annual consolidated financial statements for the year ended 30 June 2025.

These financial statements have been prepared on the going concern basis which contemplates the consolidated entity's ability to pay its debts as and when they become due and payable for a period of at least 12 months from the date of authorising the financial report for issue.

**New, revised or amended Accounting Standards and Interpretations adopted**

Any new, revised or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

**Genetic Signatures Limited**  
**Notes to the consolidated financial statements**  
**For the half-year ended 31 December 2025**

**Note 2: Financial Reporting Segments**

The consolidated entity is operated under one business segment which is the research and commercialisation of identifying individual genetic signatures to diagnose infectious diseases.

**Geographic locations**

*Asia Pacific*

The Group's head office and manufacturing operation is based in Sydney, Australia.

The Australian entity is responsible for sales into all regions not covered by the regions defined below. All intellectual property is held within the Australian entity.

*EMEA*

This business segment comprises United Kingdom and Ireland.

*Americas*

This business segment currently includes the United States. The Group is represented by employees in the United States.

	<b>Asia Pacific</b>	<b>EMEA</b>	<b>Americas</b>	<b>Eliminations</b>	<b>Total</b>
	\$'000s	\$'000s	\$'000s	\$'000s	\$'000s
<b>Consolidated – Half year ending 31 Dec 2025</b>					
Trade sales to external customer	7,879	692	110	-	8,681
Intersegment sales	291	334	80	(705)	-
<b>Total sales</b>	<u>8,170</u>	<u>1,026</u>	<u>190</u>	<u>(705)</u>	<u>8,681</u>
Segment revenue	<u>8,170</u>	<u>1,026</u>	<u>190</u>	<u>(705)</u>	<u>8,681</u>
<i>Unallocated revenue</i>					
Other revenue					2,507
<b>Total revenue</b>					<u>11,188</u>
Loss before income tax					(6,365)
Income tax					-
<b>Net Loss</b>					<u>(6,365)</u>
Segment assets	84,763	1,088	2,550	(39,362)	49,039
Segment liabilities	<u>(4,957)</u>	<u>(14,370)</u>	<u>(27,000)</u>	<u>41,379</u>	<u>(4,948)</u>
<b>Consolidated – Half year ending 31 Dec 2024</b>					
Trade sales to external customers	7,871	628	-	-	8,499
Intersegment sales	383	172	-	(555)	-
<b>Total sales</b>	<u>8,254</u>	<u>800</u>	<u>-</u>	<u>(555)</u>	<u>8,499</u>
Segment revenue	<u>8,254</u>	<u>800</u>	<u>-</u>	<u>(555)</u>	<u>8,499</u>
<i>Unallocated revenue</i>					
Other revenue					873
<b>Total revenue</b>					<u>9,372</u>
Loss before income tax					(15,200)
Income tax					-
<b>Net Loss</b>					<u>(15,200)</u>
Segment assets	89,471	2,942	3,754	(37,154)	59,013
Segment liabilities	<u>(4,737)</u>	<u>(14,470)</u>	<u>(26,250)</u>	<u>41,033</u>	<u>(4,424)</u>

**Genetic Signatures Limited**  
**Notes to the consolidated financial statements**  
**For the half-year ended 31 December 2025**

**Note 3: Disaggregation of revenue**

*Disaggregation of revenue*

The disaggregation of revenue from contracts with customers is as follows:

<b>Consolidated – Half year ending 31 Dec 2025</b>	Asia Pacific \$'000s	EMEA \$'000s	Americas \$'000s	Total \$'000s
<i>Revenue lines</i>				
Reagents & consumables	7,650	640	96	8,386
Equipment sales & rental*	228	53	14	295
Service contracts	-	-	-	-
	<u>7,878</u>	<u>693</u>	<u>110</u>	<u>8,681</u>
<i>Timing of revenue recognition</i>				
Goods transferred at a point in time	7,650	640	96	8,386
Services transferred over time	228	53	14	295
	<u>7,878</u>	<u>693</u>	<u>110</u>	<u>8,681</u>

\* includes the standalone selling price for rental of equipment placed through bundled contractual arrangements.

<b>Consolidated – Half year ending 31 Dec 2024</b>	Asia Pacific \$'000s	EMEA \$'000s	Americas \$'000s	Total \$'000s
<i>Revenue lines</i>				
Reagents & consumables	7,823	418	-	8,241
Equipment sales & rental	184	71	-	255
Service contracts	3	-	-	3
	<u>8,010</u>	<u>489</u>	<u>-</u>	<u>8,499</u>
<i>Timing of revenue recognition</i>				
Goods transferred at a point in time	7,823	418	-	8,241
Services transferred over time	187	71	-	258
	<u>8,010</u>	<u>489</u>	<u>-</u>	<u>8,499</u>

**Note 4: Revenue and Other Income**

	<b>Consolidated</b>	
	<b>31 Dec 2025</b>	<b>31 Dec 2024</b>
	<b>\$'000s</b>	<b>\$'000s</b>
<i>Sales revenue</i>		
Sale of goods & services	8,681	8,499
<i>Other income</i>		
Interest	520	881
Research & Development Tax Incentive	1,987	(53)
Other	-	45
	<u>2,507</u>	<u>873</u>
<b>Total revenue and other income</b>	<u><b>11,188</b></u>	<u><b>9,372</b></u>

**Genetic Signatures Limited**  
**Notes to the consolidated financial statements**  
**For the half-year ended 31 December 2025**

**Note 5: Expenses**

	<b>Consolidated</b>	
	<b>31 Dec 2025</b>	<b>31 Dec 2024</b>
	<b>\$'000s</b>	<b>\$'000s</b>
Profit before income tax includes the following specific expenses:		
<i>Cost of sales</i>		
Raw materials & consumables used	3,584	3,301
Provision for stock obsolescence*	263	196
Freight on materials and finished goods	520	487
	<hr/>	<hr/>
<i>Finance costs (included in Other expenses)</i>		
Interest and finance charges paid/payable for lease liabilities	28	45
	<hr/>	<hr/>
<i>Depreciation and amortisation expense</i>		
Depreciation of property, plant and equipment	835	1,008
Amortisation of right of use assets	232	232
	<hr/>	<hr/>
	1,067	1,240
	<hr/>	<hr/>
<i>Impairment expenses</i>		
Impairment of intangible assets	-	6,497
Impairment of property, plant and equipment	-	304
	<hr/>	<hr/>
	-	6,801
	<hr/>	<hr/>
<i>Superannuation expense</i>		
Defined contribution superannuation expense	545	655
	<hr/>	<hr/>

\*An assessment of inventory with an expiry date of less than 12 months was undertaken during the period. A provision was recognised for products that have a lower probability of being used before their expiry.

**Genetic Signatures Limited**  
**Notes to the consolidated financial statements**  
**For the half-year ended 31 December 2025**

**Note 6: Trade and other receivables**

	<b>Consolidated</b>	
	<b>31 Dec 2025</b>	<b>30 Jun 2025</b>
	<b>\$'000s</b>	<b>\$'000s</b>
Trade receivables	1,942	2,559
Less: Allowance for expected credit losses	(5)	(7)
	<u>1,937</u>	<u>2,552</u>
Other receivables	721	827
Interest receivable	49	-
	<u>2,707</u>	<u>3,379</u>

**Note 7: Financial assets at amortised cost**

	<b>Consolidated</b>	
	<b>31 Dec 2025</b>	<b>30 Jun 2025</b>
	<b>\$'000s</b>	<b>\$'000s</b>
Term deposits with a maturity less than 12 months	<u>12,680</u>	<u>23,822</u>

The consolidated entity assesses at period end whether its bank term deposits are held for the purpose of meeting short-term cash commitments, or for investment or other purposes. When assessing the purpose of its bank deposits, the consolidated entity considers its available cash reserves as compared to its forecasted operating cash requirements to determine whether the bank term deposit is not required to meet short-term cash commitments, it is then classified as an asset separate from cash and cash equivalents.

**Note 8: Intangible Assets**

	<b>Consolidated</b>	
	<b>31 Dec 2025</b>	<b>30 Jun 2025</b>
	<b>\$'000s</b>	<b>\$'000s</b>
At cost	-	-
Less: accumulated amortisation	-	-
	<u>-</u>	<u>-</u>

Movement in intangibles is as follows:

	<b>Software</b>	<b>Instrument</b>	<b>Total</b>
	<b>\$'000s</b>	<b>Development</b>	<b>\$'000s</b>
	<b>\$'000s</b>	<b>\$'000s</b>	<b>\$'000s</b>
Cost at 1 July 2024	2,082	4,378	6,460
Additions	251	511	762
R&D tax incentive	(109)	(222)	(331)
Disposals	-	-	-
Impairment	(2,012)	(4,667)	(6,679)
Cost at 30 June 2025	<u>212</u>	<u>-</u>	<u>212</u>
Accumulated amortisation at 1 July 2024	(212)	-	(212)
Amortisation expense	-	-	-
Accumulated amortisation at 30 June 2025	<u>(212)</u>	<u>-</u>	<u>(212)</u>
Carrying value 30 June 2025	<u>-</u>	<u>-</u>	<u>-</u>
Carrying value 31 Dec 2025	<u>-</u>	<u>-</u>	<u>-</u>

**Note 8: Intangible Assets (continued)**

Intangible assets comprised capitalised costs associated with the development of new knowledge and encompassed both the development of a sample to result instrument, and software projects related to workflow and instrument control.

In the prior year, an impairment assessment of the carrying value of these assets was performed, and accordingly an impairment expense of \$6,679,000 was recognised. The company undertook a thorough assessment of the competitive landscape, customer needs and capabilities of available instruments and software solutions in the market. This process identified that adaption of commercially available instruments could deliver a solution which was substantially the same as what was proposed with the Next Generation Instrument, is faster to market at a lower development cost, meeting regulatory and security requirements. As a result, the company ceased the internal development of the Next Generation instrument to focus on these commercially available systems which has led to the impairment of the value of intangible assets during the prior year. The impairment expense recognised in the prior year comprised \$4,667,000 attributable to instrument development and \$2,012,000 attributable to associated software development.

**Note 9: Equity – Issued Capital**

	<b>Consolidated</b>			
	<b>31 Dec 2025</b>	<b>30 June 2025</b>	<b>31 Dec 2025</b>	<b>30 June 2025</b>
	<b>Shares</b>	<b>Shares</b>	<b>\$'000s</b>	<b>\$'000s</b>
Ordinary shares – fully paid	<u>227,138,828</u>	<u>227,138,828</u>	<u>127,645</u>	<u>127,645</u>

**Note 10: Contingent liabilities**

The consolidated entity does not have any material contingent liabilities at period-end.

**Note 11: Events after the reporting period**

As outlined in the Directors Report Maria Halasz was appointed as CEO effective 2<sup>nd</sup> March 2026 and Anne Lockwood was appointed interim Managing Director effective 2<sup>nd</sup> March 2026. There has not arisen in the interval between the end of the financial period and the date of this report any other item, transaction or event of a material and unusual nature likely in the opinion of the directors of the Company to affect significantly the operations of the consolidated entity, the results of those operations or the state of affairs of the consolidated entity in future financial years.

**Note 12: Dividends**

The consolidated entity has not declared or paid a dividend during the half-year.

**Genetic Signatures Limited**  
**Notes to the consolidated financial statements**  
**For the half-year ended 31 December 2025**

**Note 13: Earnings per share**

	<b>Consolidated</b>	
	<b>31 Dec 2025</b>	<b>31 Dec 2024</b>
	<b>\$'000s</b>	<b>\$'000s</b>
Loss after income tax	(6,365)	(15,200)
Loss after income tax attributable to the owners of Genetic Signatures Limited	(6,365)	(15,200)
	<b>Number</b>	<b>Number</b>
Weighted average number of ordinary shares used in calculating basic earnings per share	227,138,828	220,819,699
Adjustments for calculation of diluted earnings per share:		
Options over ordinary shares	-	892,304
Weighted average number of ordinary shares used in calculating diluted earnings per share	227,138,828	221,712,003
	<b>Cents</b>	<b>Cents</b>
Basic loss per share	(2.80)	(6.88)
Diluted loss per share	(2.80)	(6.88)

**Note 14: Capital commitments**

There are no material current capital commitments.

In the directors' opinion:

- The attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- The attached financial statements and notes give a true and fair view of the consolidated entity's financial position as at 31 December 2025 and of its performance for the financial half-year ended on that date; and
- There are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the directors



Caroline Waldron  
Independent Chair

26 February 2026  
Sydney



Tel: +61 2 9251 4100  
Fax: +61 2 9240 9821  
www.bdo.com.au

Parkline Place  
Level 25, 252 Pitt Street  
Sydney NSW 2000  
Australia

## INDEPENDENT AUDITOR'S REVIEW REPORT

To the members of Genetic Signatures Limited

### Report on the Half-Year Financial Report

#### Conclusion

We have reviewed the half-year financial report of Genetic Signatures Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 31 December 2025, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the half-year ended on that date, material accounting policy information and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the Group does not comply with the Corporations Act 2001 including:

- i. Giving a true and fair view of the Group's financial position as at 31 December 2025 and of its financial performance for the half-year ended on that date; and
- ii. Complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001.

#### Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to the audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* which has been given to the directors of the Company, would be the same terms if given to the directors as at the time of this auditor's review report.

#### Responsibility of the directors for the financial report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act*



2001 and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

**Auditor's responsibility for the review of the financial report**

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2025 and its financial performance for the half-year ended on that date and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

BDO Audit Pty Ltd

BDO

A handwritten signature in blue ink, appearing to read 'Rajnil Kumar'.

Rajnil Kumar  
Director

Sydney, 26 February 2026